Author: admin

LONDON — Eight healthy babies were born in Britain with the help of an experimental technique that uses DNA from three people to help mothers avoid passing devastating rare diseases to their children, researchers reported Wednesday.

Most DNA is found in the nucleus of our cells, and it’s that genetic material — some inherited from mom, some from dad — that makes us who we are. But there’s also some DNA outside of the cell’s nucleus, in structures called mitochondria. Dangerous mutations there can cause a range of diseases in children that can lead to muscle weakness, seizures, developmental delays, major organ failure and death.

Testing during the in vitro fertilization process can usually identify whether these mutations are present. But in rare cases, it’s not clear.

Researchers have been developing a technique that tries to avoid the problem by using the healthy mitochondria from a donor egg. They reported in 2023 that the first babies had been born using this method, where scientists take genetic material from the mother’s egg or embryo, which is then transferred into a donor egg or embryo that has healthy mitochondria but the rest of its key DNA removed.

The latest research “marks an important milestone,” said Dr. Zev Williams, who directs the Columbia University Fertility Center and was not involved in the work. “Expanding the range of reproductive options … will empower more couples to pursue safe and healthy pregnancies.”

Using this method means the embryo has DNA from three people — from the mother’s egg, the father’s sperm and the donor’s mitochondria — and it required a 2016 U.K. law change to approve it. It is also allowed in Australia but not in many other countries, including the U.S.

Experts at Britain’s Newcastle University and Monash University in Australia reported in the New England Journal of Medicine Wednesday that they performed the new technique in fertilized embryos from 22 patients, which resulted in eight babies that appear to be free of mitochondrial diseases. One woman is still pregnant.

One of the eight babies born had slightly higher than expected levels of abnormal mitochondria, said Robin Lovell-Badge, a stem cell and developmental genetics scientist at the Francis Crick Institute who was not involved in the research. He said it was still not considered a high enough level to cause disease, but should be monitored as the baby develops.

Andy Greenfield, a reproductive health expert at the University of Oxford who was not involved in the study, called it “highly significant,” adding that the method of exchanging mitochondria would only be used for a small number of women for whom other ways of avoiding passing on genetic diseases, like testing embryos at an early stage, was not effective.

“The technique was first made lawful 10 years ago, so we have all been waiting for this report,” he told NBC News over email. “Fortunately, the children appear to be healthy.”

Follow-up of these children — potentially for many years — would be important to ensure they remain healthy, he said.

Lovell-Badge said the amount of DNA from the donor is insignificant, noting that any resulting child would have no traits from the woman who donated the healthy mitochondria. The genetic material from the donated egg makes up less than 1% of the baby born by using this technique.

“If you had a bone marrow transplant from a donor … you will have much more DNA from another person,” he said.

In the U.K., every couple seeking a baby born through donated mitochondria must be approved by the country’s fertility regulator.

Critics have previously raised concerns, warning that it’s impossible to know the impact these sorts of novel techniques might have on future generations.

“Currently, pronuclear transfer is not permitted for clinical use in the U.S., largely due to regulatory restrictions on techniques that result in heritable changes to the embryo,” Williams, of Columbia, said in an email. ”Whether that will change remains uncertain and will depend on evolving scientific, ethical, and policy discussions.”

For about a decade, Congress has included provisions in annual funding bills banning the Food and Drug Administration from accepting applications for clinical research involving techniques, “in which a human embryo is intentionally created or modified to include a heritable genetic modification.”

But in countries where the technique is allowed, advocates say it could provide a promising alternative for some families.

Liz Curtis, whose daughter Lily died of a mitochondrial disease in 2006, now works with other families affected by them. She said it was devastating to be told there was no treatment for her eight-month-old baby and that death was inevitable.

She said the diagnosis “turned our world upside down, and yet nobody could tell us very much about it, what it was or how it was going to affect Lily.” Curtis later founded the Lily Foundation in her daughter’s name to raise awareness and support research into the disease, including the latest work done at Newcastle University.

“It’s super exciting for families that don’t have much hope in their lives,” Curtis said.

The Human Fertilisation and Embryology Authority, the UK’s fertility regulator, welcomed the findings, adding that the technique would legally only be available to those at very high risk of passing the disease onto their children.

As of this month, 35 patients have been authorized to undergo the procedure.

A new research paper was published in Aging (Aging-US) Volume 17, Issue 6, on June 9, 2025, titled “Developing a quantitative estimate of muscle age acceleration by a novel phenotypic clock: cross-sectional study in healthy, middle-aged and older adults.”

In this study, led by first authors Lucia Ventura, Antonella Cano and Marco Morrone, along with corresponding author Franca Deriu from the University of Sassari, researchers introduce a new method to predict how muscles age, offering an early warning system for sarcopenia, the condition of age-related muscle loss. The study demonstrates how a simple, low-cost approach can identify middle-aged and older adults at higher risk for declining muscle health, allowing timely preventive strategies.

The researchers developed a tool called Muscle Age Acceleration (MAA), which measures how quickly an individual’s muscles are aging compared to their actual age. By analyzing physical performance tests and body composition in 215 healthy participants aged 50 to 90 years, the researchers found that about 25% of individuals experience accelerated muscle aging. These individuals had a higher probability of developing sarcopenia, despite appearing healthy and not yet having received a diagnosis of the condition.

Sarcopenia reduces muscle strength and physical performance, being a growing concern for older adults. It contributes to frailty, falls, and an increased risk of disability. Despite greater awareness, this condition often goes undetected until significant muscle loss occurs. This new muscular clock offers an opportunity to detect subtle changes in muscle health before they progress to more severe stages.

By using common tests such as handgrip strength, walking speed, and mobility assessments, the MAA tool can classify individuals as having accelerated, normal, or decelerated muscle aging. Those with accelerated muscle aging also showed small changes in blood markers, suggesting early and hidden inflammation linked to muscle decline. This finding indicates that MAA may act as both a predictor of muscle-related aging and an indicator of overall health risks.

“According to MAA, three trajectories were identified: accelerated agers displayed higher risk for sarcopenia (19%), as compared to normal (9%; p < 0.0001) and decelerated (2%; p < 0.0001), paralleled by significant subclinical alterations of haemato-chemical markers in accelerated agers.”

If validated in future studies, this innovative approach could transform how clinicians and caregivers screen for early signs of sarcopenia. Its simplicity makes it suitable for use in clinics and community settings, helping older adults maintain independence and quality of life as they age.

In summary, these findings highlight the importance of monitoring muscle health and physical performance in older adults. By detecting early signs of muscle aging with tools like MAA, interventions such as exercise and dietary changes can be introduced earlier, potentially delaying or preventing sarcopenia and its complications.

In a study conducted in Uganda and published in JAMA Surgery, researchers from Karolinska Institutet evaluated a new surgical method for treating groin hernias in women. The method could become an alternative in resource-limited settings where laparoscopic techniques are not generally available.

Groin hernia repair is the most common general surgical procedure in the world. Groin hernias are more common in men, but women are more likely to experience complications due to this condition.
Many women in low- and middle-income countries who need surgery for groin hernias lack access to laparoscopy (keyhole surgery). To evaluate a new method using open surgery, the researchers conducted a randomised clinical trial at two publicly funded hospitals in Uganda. The study included 200 women who underwent groin hernia surgery and were followed up after two weeks and after one year.

Femoral hernias were common

There are two main types of groin hernias, called inguinal and femoral hernias. The evaluation showed that the new surgical method was effective for both femoral and inguinal groin hernias.

Its effectiveness for both types is particularly important as the study also showed that nearly 45 percent of the women had femoral hernias, which carry a higher risk of complications.

The fact that so many of the women had femoral hernias was unexpected and highlights the need to develop effective, safe and accessible methods.”

Alphonsus Matovu, PhD, Department of Molecular Medicine and Surgery, Karolinska Institutet and first author of the article

Millions of women affected

The results are promising as the new method could be developed into a viable alternative where access to advanced laparoscopic surgery is limited.

“Women with groin hernias can suffer serious and even fatal complications and therefore need access to effective surgical methods,” says Jenny Löfgren, docent at the same department and last author of the article. “The new method could become a valuable tool to improve care for millions of women”.

The method needs further evaluation, and the researchers will also follow up with the study participants five years after surgery to ensure long-term results. To improve treatment, the new method will also be compared with other surgical methods, both open and laparoscopic.

The Swedish Research Council funded the study.